Dermatology

Zasocitinib beats deucravacitinib in head-to-head psoriasis trial; lebrikizumab improves hand and foot eczema; GLP-1 users report nail detachment

• Research Sept 30, 2026
  Zasocitinib tops deucravacitinib on PASI 100, 36.5% versus 13.9%, in head-to-head phase 3 psoriasis trial
  Takeda announced Sept. 30 results from the LATITUDE Atlas trial, presented in late-breaking and oral sessions at the European Academy of Dermatology and Venereology Congress. The trial enrolled 606 participants with moderate-to-severe plaque psoriasis who received zasocitinib 30 mg or deucravacitinib 6 mg once daily up to week 16. At week 16, 36.5% of zasocitinib patients reached PASI 100 versus 13.9% with deucravacitinib, 62.5% versus 34.0% reached PASI 90 and 43.2% versus 18.5% reached sPGA 0 (P < .001 for each). Zasocitinib is under review by the U.S. Food and Drug Administration and the European Medicines Agency, the company said.
  Sources: Takeda, Dermatology Times
• Research Sept 30, 2026
  Lebrikizumab yields clear or almost clear hands and feet in 53% versus 27% with placebo in phase 3b ADtouch trial
  Eli Lilly said Sept. 30 that lebrikizumab (Ebglyss) met its primary and secondary end points at week 16 in the phase 3b ADtouch trial, presented at the European Academy of Dermatology and Venereology Congress. Clear or almost clear hands and feet, the primary end point, was reached by 53% of patients receiving lebrikizumab versus 27% receiving placebo. The randomized, double-blind, placebo-controlled trial included 221 adults and adolescents 12 and older with moderate-to-severe atopic hand and foot dermatitis and an inadequate response to topical therapies, Dermatology Times reported. Lilly said it submitted the data to the Food and Drug Administration.
  Sources: Eli Lilly and Company, Dermatology Times
• Research Sept 29, 2026
  Nemolizumab responses hold through three years in ARCADIA atopic dermatitis extension, Galderma says
  Galderma said Sept. 29 that three-year data from the ARCADIA open-label long-term extension of nemolizumab (Nemluvio), to be presented Oct. 1 at the European Academy of Dermatology and Venereology Congress, showed in observed case analyses that up to 91% of patients with moderate-to-severe atopic dermatitis achieved EASI-75 and up to 67% achieved clear or almost clear skin (IGA 0/1). Up to 88% achieved clinically meaningful itch relief and up to 73% an itch-free or nearly itch-free state. The company said the safety profile remained consistent with previous findings, with no new safety signals.
  Source: Galderma (Business Wire)
• Research Oct 1, 2026
  Nail detachment reported by 39% of GLP-1 receptor agonist users versus 9% of controls in EADV study
  A multinational, cross-sectional, case-control study presented at the European Academy of Dermatology and Venereology Congress compared 575 GLP-1 receptor agonist users with 1,329 people with type 2 diabetes or obesity who had never taken the drugs, recruited across France, the U.S., Brazil and Mexico, HCPLive reported Oct. 1. Nail detachment, or onycholysis, was reported by 39% of users versus 9% of controls, and nail discoloration by 46% versus 17%. At least one nail disorder was reported by 66% of users versus 53% of controls.
  Source: HCPLive